- The trend backdrop is active with a 1-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
PRN
TOR
Week ended 07 Aug 2026
Weekly Investor Report
Profound Medical Corp. · Healthcare · Medical Devices
Latest close
10.30 CAD
-0.8%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 9.9% above the Trend Line and sits at 70.7% of its 52-week range. The latest completed week returned -0.8%, after a 2.5% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 50/100.
Setup score
57
out of 100
Latest Close
10.30 CAD
7 Aug 2026
1W Return
-0.8%
latest completed week
4W Return
2.5%
short-term follow-through
12W Return
8.3%
quarterly tape
Trend Breadth
36.5%
19 of 52 weeks active
Volume Ratio
2.2x
vs 13-week average
- No major top-level risk cluster is currently dominant.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-0.8%
Latest completed week; four-week move 2.5%.
Indicator stack
24/78
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
20 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 9.9% above the Trend Line and sits at 70.7% of its 52-week range. The latest completed week returned -0.8%, after a 2.5% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.2x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.4712-week average 0.37
12-week confirmation
Trend active1/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership6/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.47Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 2.5% over four weeks, 8.3% over 12 weeks, and 33.2% over one year. The current trend has remained active for 1 consecutive weeks.
Performance by holding period
Active trend streak1 weeks
Active weeks in one year19
Trend breadth36.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.06Latest activity-pressure read.
Pressure change115.4%Four-week change in activity pressure.
Leadership3.81Latest relative-leadership reading.
RS change-14.9%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 73%
Model confidence 68%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength9/100Blend of value, momentum, and quality. Underlying universe rank 92; rank 1 is best.
Value16/100Relative valuation strength. Underlying universe rank 85; rank 1 is best.
Quality3/100Profitability and accounting quality. Underlying universe rank 98; rank 1 is best.
Momentum67/100Medium-term price momentum. Underlying universe rank 34; rank 1 is best.
Growth87/100Revenue and earnings growth. Underlying universe rank 14; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 19.9x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -11.7% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 71.1% Gross profit retained from each unit of revenue.
- Operating margin
- -202.6% Operating profit retained from revenue.
- Free-cash-flow margin
- -206.0% Free cash flow generated from revenue.
- Return on invested capital
- -172.3% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 50.7% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -11.3% Net share repurchases relative to market value.
- Shareholder yield
- -11.3% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 20 relevant articles.
0 positive · 19 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-16.9%Distance below the 52-week high.
13-week volatility3.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher16 of 269 weeks finished lower.
Best week+22.6%Week of 27 Mar.
Worst week-31.5%Week of 6 Mar.
Latest week-0.8%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains8
Flat weeks1
Modest losses5
Sharp losses4
Recent vol3.0%13-week weekly-return volatility.
Base vol9.2%52-week weekly-return volatility.
Up/down split30/21Count of positive and negative weeks in the 52-week window.
Average skew6.5% / -6.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorCA Healthcare
4-week rank15 / 46
Group average0.0%
Trend breadth34.8%
Trend34.8%active weekly trend signals
MD47.8%positive activity pressure
RS23.9%positive relative leadership
Four-week leaders
IndustryCA Medical Devices
4-week rank1 / 1
Group average2.5%
Trend breadth100.0%
Trend100.0%active weekly trend signals
MD100.0%positive activity pressure
RS100.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape54/100
Trend, activity pressure, participation, and risk combine to a 54/100 tape read.
Indicator analysis49/100Latest 12-week confirmation: trend 1/12, activity pressure 12/12, relative leadership 6/12.
Activity pressure 0.47; No reversal markers Factors21/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 92; Small Cap Core rank 89 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 20 relevant articles.
Medical Devices & Supplies - Diversified Stocks Q2 Results: Benchmarking Neogen (NASDAQ:NEOG) Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 10.30 CAD | -0.8% | 9.37 CAD | 10.08 CAD | 1.06 | 3.81 | 87.9K | On |
| 31 Jul 2026 | 10.38 CAD | 1.0% | 9.42 CAD | 10.10 CAD | 1.01 | 8.08 | 95.1K | Off |
| 24 Jul 2026 | 10.28 CAD | 7.1% | 9.42 CAD | 10.11 CAD | 0.77 | 6.66 | 56.9K | Off |
| 17 Jul 2026 | 9.60 CAD | -4.5% | 9.42 CAD | 10.15 CAD | 0.57 | -0.02 | 58.0K | Off |
| 10 Jul 2026 | 10.05 CAD | 3.1% | 9.45 CAD | 10.19 CAD | 0.49 | 4.48 | 103.6K | Off |
| 3 Jul 2026 | 9.75 CAD | 4.4% | 9.45 CAD | 10.24 CAD | 0.28 | 1.45 | 0 | Off |
| 26 Jun 2026 | 9.34 CAD | -2.7% | 9.43 CAD | 10.29 CAD | 0.20 | -2.23 | 2.7K | Off |
| 19 Jun 2026 | 9.60 CAD | 3.6% | 9.42 CAD | 10.34 CAD | 0.15 | 0.27 | 2.1K | Off |
| 12 Jun 2026 | 9.27 CAD | -0.7% | 9.38 CAD | 10.38 CAD | 0.09 | -3.47 | 900 | Off |
| 5 Jun 2026 | 9.34 CAD | -2.0% | 9.38 CAD | 10.43 CAD | 0.05 | -1.76 | 18.6K | Off |
| 29 May 2026 | 9.53 CAD | 0.2% | 9.35 CAD | 10.50 CAD | 0.12 | -0.91 | 27.8K | Off |
| 22 May 2026 | 9.51 CAD | 0.0% | 9.31 CAD | 10.55 CAD | 0.03 | -0.27 | 17.4K | Off |
| 15 May 2026 | 9.51 CAD | 1.0% | 9.25 CAD | 10.59 CAD | -0.03 | 1.66 | 47.8K | Off |
| 8 May 2026 | 9.42 CAD | 0.3% | 9.19 CAD | 10.64 CAD | -0.23 | 0.16 | 108.8K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.